| Bioactivity | Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries. IC50 Value: Target: in vitro: Pramiracetam sulfate did not exhibit any affinity in vitro for dopaminergic , GABAergic, serotoninergic, adrenergic, muscarinic, adenosine (IC50 > 10 uM), and benzodiazepine receptors (IC50 > 1 uM) binding sites [1].in vivo: In a double-blind, randomized design, two groups of six subjects each received alternating placebo and single 400, 800, 1,200, and 1,600 mg oral doses of pramiracetam after an overnight fast. Mean (+/- SD) peak plasma concentrations of the four dose groups (2.71 +/- 0.54, 5.40 +/- 1.34, 6.13 +/- 0.71, 8.98 +/- 0.71 micrograms/mL) were attained between two to three hours following drug administration [2]. Two doses of pramiracetam (7.5 mg/kg and 15 mg/kg) were administered daily prior to testing for 7 weeks in a 16-arm radial maze in which nine arms were baited with food [3]. | ||||||||||||
| Name | Pramiracetam | ||||||||||||
| CAS | 68497-62-1 | ||||||||||||
| Formula | C14H27N3O2 | ||||||||||||
| Molar Mass | 269.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Warner Lambert, et al. Some Neurochemical Properties of Pramiracetam (CI-879), A New Cognition-Enhancing Agent. [2]. Chang T, et al. Pharmacokinetics of oral pramiracetam in normal volunteers. J Clin Pharmacol. 1985 May-Jun;25(4):291-5. |
Pramiracetam
CAS: 68497-62-1 F: C14H27N3O2 W: 269.38
Pramiracetam is a nootropic drug derived from piracetam, and is more potent. Pramiracetam reportedly improved cognitive
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.